Coya Therapeutics (COYA) Investor presentation summary

Investment highlights

• Focused pipeline targets neurodegenerative diseases with COYA 302 (ALS, FTD, AD, Parkinson's) and COYA 303 (AD).

• Near-term ALS Phase 2 data readout expected Q1 2027; FTD Phase 2a to start H2 2026.

• Early clinical studies show stabilization in ALS and cognitive stability in FTD.

• Nobel-recognized science underpins Treg-directed approach.

• Strategic partnership with Dr. Reddy's offers up to $700M in milestones and mid-teen royalties.

Scientific and clinical rationale

• Treg dysfunction drives neuroinflammation and disease progression in ALS and FTD.

• Combination therapy (low-dose IL-2 + CTLA4-Ig) restores Treg function and immune balance.

• Early clinical data in ALS and FTD show disease stabilization and improved Treg activity.

• Nobel Prize awarded to SAB member for Treg biology discovery.

ALS program overview

• ALS is rapidly fatal with high unmet need; current therapies only modestly effective.

• Phase 2 ALSTARS study of COYA 302 is enrolling; topline data expected Q1 2027.

• Investigator-initiated study showed 3 of 4 ALS patients stable or improved over 48 weeks.

• Fast Track Designation granted for COYA 302 in ALS.